Clinical trial NCT00066677 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: rhumab-vegf, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    stopped accordining to early stopping rule for futility
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the pancreas

               -  Metastatic disease

          -  Unidimensionally measurable disease outside of the pancreas

               -  At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by
                  spiral CT scan

          -  Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic
             disease unless disease has recurred within 6 months after treatment with neoadjuvant
             or adjuvant gemcitabine-containing therapy

          -  No brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)

          -  No bleeding diathesis or coagulopathy

        Hepatic

          -  Bilirubin no greater than upper limit of normal (ULN)

          -  AST and ALT no greater than 1.5 times ULN

          -  INR no greater than ULN

          -  PTT no greater than ULN

        Renal

          -  Creatinine no greater than 2.0 mg/dL

          -  No clinically significant renal impairment

          -  Urine protein:creatinine ratio ≥ 1.0

        Cardiovascular

          -  No prior myocardial infarction

          -  No prior stroke

          -  No clinically significant cardiovascular disease

          -  No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on
             medication)

          -  No unstable angina

          -  No New York Heart Association class II-IV congestive heart failure

          -  No serious cardiac dysrhythmia requiring medication

          -  No peripheral vascular disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history or evidence of CNS disease (e.g, primary brain tumor or seizures not
             controlled with standard medical therapy)

          -  No other medical condition that would preclude study participation

          -  No psychiatric condition that would preclude study participation

          -  No other prior or concurrent malignancy that would preclude study participation

          -  No significant traumatic injury within the past 28 days

          -  No serious, nonhealing wound, ulcer, or bone fracture

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent prophylactic granulocyte or platelet growth factors

        Chemotherapy

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy

        Surgery

          -  More than 7 days since prior fine needle aspirations or core biopsies

          -  More than 28 days since prior surgery (except closed biopsy or access port placement)

          -  More than 28 days since prior open biopsy

          -  No concurrent surgery

        Other

          -  More than 4 weeks since prior experimental drug study participation

          -  More than 4 weeks since prior investigational drugs

          -  No other concurrent experimental drug study participation